方萍

    [摘要] 目的 探讨尼妥珠单抗同步放化疗对局部晚期不可切除食管癌的疗效及应用安全性，为临床选取治疗方案提供参考。 方法 选取2017年1—12月解放军联勤保障部队第九○二医院收治的局部晚期不可切除食管癌患者94例为研究对象。根据随机数字表法将其分为观察组与对照组，每组47例。对照组采用同步放化疗治疗，观察组在对照组的基础上联合采用尼妥珠单抗治疗。比较两组近期疗效，1、2年生存率，毒副作用严重程度。结果 观察组治疗有效率、控制率高于对照组，差异均有统计学意义(均P 0.05)。 结论 尼妥珠单抗同步放化疗治疗局部晚期不可切除食管癌能够提高近期效果，延长患者生存期，且耐受性好、安全性高，可推广应用。

    [关键词] 食管癌;晚期;尼妥珠单抗;同步放化疗;疗效;安全性

    [中图分类号] R735.1? ? ? ? ? [文献标识码] A? ? ? ? ? [文章编号] 1673-7210(2020)08(a)-0152-04

    [Abstract] Objective To explore the efficacy and safety of Nitzumab combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced unresectable esophageal cancer， and to provide a reference for clinical treatment. Methods From January to December 2017， 94 cases with locally advanced unresectable esophageal cancer in the 902th Hospital of Chinese′s People′s Liberation Army were selected as the study subjects. They were divided into the observation group and the control group according to the random number table method ......